From Investopedia:

Viking Therapeutics saw its shares double after positive results from a Phase 2 study of its weight-loss drug, VK2735. Patients experienced significant weight reduction, with some seeing a drop of up to 14.3%. CEO Brian Lian expressed optimism for further development and plans to discuss next steps with regulators. Shares soared 121% to $85.05.



Read more at Investopedia: Viking Therapeutics Stock More Than Doubles on Weight-Loss Drug Trial Results